A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

NCT05963022 on ClinicalTrials.gov · last registry update 2025-10-21

A small phase 3 — 206 participants, against a typical 424. The sponsor logged completion for 9 October 2024. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 206
Started: 2023-08-21
Primary completion: 2024-10-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.